March 1, 2018 / 12:11 PM / 5 months ago

BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56

March 1 (Reuters) - Intra-Cellular Therapies Inc:

* INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q4 LOSS PER SHARE $0.56

* CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TOTALED $464.3 MILLION AT DEC 31, 2017, VERSUS $384.1 MILLION AT DEC 31, 2016

* INTRA-CELLULAR THERAPIES - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE USED PRIMARILY TO ADVANCE LUMATEPERONE DEVELOPMENT PROGRAM

* INTEND TO SUBMIT A NEW DRUG APPLICATION FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA BY MID-2018

* PRE-NDA MEETING WITH FDA IS SCHEDULED TO BE HELD IN LATE Q1 2018 FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below